Halozyme Therapeutics Inc (HALO)

Return on equity (ROE)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	281,594	253,908	233,705	181,636	202,129	211,197	366,150	434,923	402,710	409,104	228,724	163,083	129,085	21,524	-39,698	-80,139	-72,240	-39,969	-42,804	-51,073
Total stockholders’ equity	US$ in thousands	83,808	249,181	151,033	65,850	169,798	96,991	293,171	260,256	196,953	281,674	119,746	67,595	151,047	98,988	105,577	58,042	91,765	245,353	260,052	260,047
ROE		336.00%	101.90%	154.74%	275.83%	119.04%	217.75%	124.89%	167.11%	204.47%	145.24%	191.01%	241.26%	85.46%	21.74%	-37.60%	-138.07%	-78.72%	-16.29%	-16.46%	-19.64%

December 31, 2023 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $281,594K ÷ $83,808K
= 336.00%

To analyze Halozyme Therapeutics Inc.'s return on equity (ROE) based on the data provided, we observe significant fluctuations in ROE over the past eight quarters. ROE is a measure of a company's profitability that highlights how effectively a company generates profit from its equity.

In Q4 2023, Halozyme Therapeutics Inc. reported a remarkably high ROE of 336.00%, signifying strong efficiency in utilizing equity to generate profit. This substantial increase from the previous quarter's ROE of 101.90% indicates a significant improvement in profitability.

The company's ROE in Q3 2023, Q2 2023, and Q1 2023 stood at 101.90%, 154.74%, and 275.83%, respectively. These figures demonstrate a fluctuating trend in profitability over these quarters, with Q1 2023 showing the highest ROE during this period.

Comparing the recent quarters to the same periods in 2022, we see varying levels of ROE. Q4 2023 exhibited a notable increase compared to Q4 2022, whereas Q3 2023 showed a decline from the previous year's corresponding quarter.

Overall, Halozyme Therapeutics Inc. has experienced fluctuations in its return on equity over the past eight quarters, with Q4 2023 recording a particularly high ROE. Further analysis would be beneficial to understand the factors driving these changes and to assess the sustainability of the company's profitability performance.